/
Roundtable

What Would Encourage You to Perform Preclinical Trials in Mexico?

Wed, 09/05/2018 - 16:53

Every year, Mexico increases its capabilities for clinical trials. Although the country is strong in Phase II and III studies, Phase I trials are almost never carried out in the country, much less pre-clinical trials. Mexico’s population, numerous research institutes and an excellent academic and scientific base should make the country an attractive destination for Phase I and pre-clinical trials. Mexico Health Review spoke with CROs and clinical research experts to find out the reasons these trials are not performed in the country and how to bring about change.

Israel Vega

Clinical Operations Manager
PRA Health Sciences

Mexico performs a very small number of Phase I clinical trials since Mexican regulation forbids paying patients for their participation in clinical trials, something that does not happen in other countries such as the US, England or some countries in Asia. Phase I trials are performed with healthy patients who are sometimes only motivated to participate in the trials due to the economic benefits, but as these are unavailable in Mexico there is little interest from the general public to participate. Phase II to IV studies involve sick patients throughout several stages of the disease who are willing to participate in the trials as it provides a potential cure for their diseases.

Melisa Rosale

Melissa Rosales

Director General
RM Pharma

Phase I studies are virtually non-existent in the country. I think we need more trained staff to carry out research and attract projects to the country because we already have the necessary infrastructure. Investment for Phase I clinical research should be aimed at training nurses, doctors and other health workers to achieve this goal. Greater openness from the government can maximize Mexico’s infrastructure and its opportunities in clinical research.

Hector Ávila

Hector Ávila

Director General
Cecyc Pharma

Mexico has the ideal conditions for the development of pre-clinical Phase I trials. We have the capacity, knowledge and infrastructure, so we just need support for researchers in this field. The government and the pharmaceutical segment must push for a more assertive communication of these favorable conditions, both domestically and internationally